Jason Dinges

Chairman, Investor Director & Board Member

Jason joined the Board of CellCentric in March 2017 and became Chair in January 2022.

Jason received his B.S. from Illinois Wesleyan University in 1998, a Ph.D. in genetics from Iowa State in 2003, and his J.D. from the University of Iowa College of Law, with highest distinction, in 2006. He spent 5 years as an intellectual property attorney with Foley & Lardner LLP, before joining Morningside Technology Advisory LLC.

Morningside is a diversified investment group founded in 1986, by the Chan family, to make private equity and venture capital investments. Jason has represented Morningside as intellectual property counsel since 2011, and has extensive experience with venture-backed biotechnology companies. In addition to CellCentric, he serves on the board of Morningside portfolio companies Adiso Therapeutics, Alentis Therapeutics, ClearB Therapeutics, Geneoscopy, Prilena, Inotrem, ZielBio, Enyo Pharma, and Vesigen.